China Pharma Holdings, Inc. (CPHI) stock
CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 18, 2026Score 4/30
$0.51+0.01 (+2.18%)
Close on Nov 18, 2026Market cap $21.98MP/E –Yield –
China Pharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
China Pharma's free cash flow for the twelve months ending Dec 31, 2025 was $88.94K. For fiscal 2025 it was $88.94K. Over ten years it grew -31.7% a year on average. The highest annual figure on record is $27.39M in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.94K | – |
| FY2024 | Dec 31, 2024 | -$444.47K | – |
| FY2023 | Dec 31, 2023 | -$711.20K | – |
| FY2022 | Dec 31, 2022 | -$811.51K | – |
| FY2021 | Dec 31, 2021 | -$687.89K | – |
| FY2020 | Dec 31, 2020 | -$909.57K | -292.6% |
| FY2019 | Dec 31, 2019 | $472.31K | -74.2% |
| FY2018 | Dec 31, 2018 | $1.83M | +159.8% |
| FY2017 | Dec 31, 2017 | $704.74K | -73.9% |
| FY2016 | Dec 31, 2016 | $2.70M | -33.0% |
| FY2015 | Dec 31, 2015 | $4.04M | +294.0% |
| FY2014 | Dec 31, 2014 | $1.02M | -96.3% |
| FY2013 | Dec 31, 2013 | $27.39M | +620.7% |
| FY2012 | Dec 31, 2012 | $3.80M | -32.0% |
| FY2011 | Dec 31, 2011 | $5.59M | -28.8% |
| FY2010 | Dec 31, 2010 | $7.85M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $151.54K | -45.7% |
| Q3 FY2025 | Sep 30, 2025 | -$204.97K | – |
| Q2 FY2025 | Jun 30, 2025 | $274.37K | -55.2% |
| Q1 FY2025 | Mar 31, 2025 | -$132.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $279.23K | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.73K | – |
| Q4 FY2022 | Dec 31, 2022 | $611.86K | – |
| Q3 FY2022 | Sep 30, 2022 | -$33.43K | – |
| Q2 FY2022 | Jun 30, 2022 | -$509.11K | -189.7% |
| Q1 FY2022 | Mar 31, 2022 | -$880.83K | – |
| Q4 FY2021 | Dec 31, 2021 | -$205.17K | – |
| Q3 FY2021 | Sep 30, 2021 | -$866.82K | – |
| Q4 FY2020 | Dec 31, 2020 | $567.44K | – |
| Q3 FY2020 | Sep 30, 2020 | -$483.82K | -203.4% |
| Q2 FY2020 | Jun 30, 2020 | -$401.24K | -203.7% |
| Q1 FY2020 | Mar 31, 2020 | -$591.95K | – |
| Q4 FY2019 | Dec 31, 2019 | -$72.37K | -108.4% |
| Q3 FY2019 | Sep 30, 2019 | $468.04K | -46.8% |
| Q2 FY2019 | Jun 30, 2019 | $386.96K | – |
| Q1 FY2019 | Mar 31, 2019 | -$310.33K | -159.7% |
| Q4 FY2018 | Dec 31, 2018 | $856.62K | -1.3% |
| Q3 FY2018 | Sep 30, 2018 | $879.94K | +32.8% |
| Q2 FY2018 | Jun 30, 2018 | -$425.70K | – |
| Q1 FY2018 | Mar 31, 2018 | $520.11K | – |
| Q4 FY2017 | Dec 31, 2017 | $867.61K | -36.5% |
| Q3 FY2017 | Sep 30, 2017 | $662.52K | – |
| Q2 FY2017 | Jun 30, 2017 | -$808.52K | – |
| Q1 FY2017 | Mar 31, 2017 | -$16.86K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.37M | – |
See a number that looks wrong?